Expert Trials conducted at TECCRO
At TECCRO, we are dedicated to pushing the boundaries of clinical research, delivering insights that drive innovation in healthcare. Our trials not only generate comprehensive data on emerging research domains but also offer novel solutions that benefit both the healthcare community and the public. Through our commitment to cutting-edge treatments and rigorous ethical standards, TECCRO is at the forefront of advancing medical science.
TECCRO: Addressing Challenges in Facial Rejuvenation – The Lower Eyelid Area
One of the most intricate aspects of facial rejuvenation is effectively treating the lower eyelid area, particularly the tear trough deformity. To address this, TECCRO conducted an expert clinical trial from December 2017 to December 2019, focusing on the use of low G prime and high G prime fillers for this issue. This study was initiated to explore more effective treatments in this delicate area.
Prior to starting the trial, TECCRO secured ethical clearance from the Institutional Ethics Committee of The Esthetic Clinics, ensuring that all procedures adhered to the highest standards of research ethics, with patient safety and well-being being top priorities throughout the study.
The trial involved 30 subjects, both male and female, aged 35-60 years, selected based on specific inclusion and exclusion criteria. The study demonstrated marked improvements in appearance and skin quality, proving the effectiveness of the treatments while minimizing invasiveness. It also provided insights into the use of low and high G prime fillers, and compared the benefits of conventional techniques versus lateral injection techniques.
Upon completion, the findings were meticulously documented and published in the peer-reviewed Journal of Cosmetic Dermatology. This publication underscores TECCRO’s commitment to advancing cosmetic dermatology through rigorous research and contributes valuable insights to the field.
For more detailed information about this groundbreaking study, please refer to the published article via the link provided below.
Link for the Paper- https://doi.org/10.1111/jocd.14407
Advancing Administrative Technique for Androgenetic Alopecia
Androgenetic alopecia, increasingly prevalent among both men and women, is a condition that requires innovative treatment approaches. At TECCRO, our ongoing Clinical Trial 02 is focused on addressing this issue with cutting-edge therapies. The trial commenced in June 2024, with the primary objective of assessing and comparing the safety and efficacy of QR678 Neo® when administered via intradermal injection (Nappage), Dermapen, and Dermapen combined with Hyaluronic acid. The study involved participants of 75 both male and female, aged between 20 and 70 years. The participants were chosen based on specific inclusion and exclusion criteria to ensure the integrity and relevance of the study..
Each group is being monitored to determine which treatment approach yields the most favorable outcomes for enhancing hair growth in individuals with androgenetic alopecia.
This trial is being conducted in full compliance with ethical standards, with approval from the Institutional Ethics Committee of The Esthetic Clinics. The study is designed to prioritize patient safety and well-being, ensuring that all procedures adhere to the highest ethical and clinical research standards.
